Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.958
+0.070 (7.84%)
At close: Mar 9, 2026, 4:00 PM EDT
0.950
-0.007 (-0.76%)
After-hours: Mar 9, 2026, 6:08 PM EDT
Tenaya Therapeutics Employees
Tenaya Therapeutics had 97 employees as of December 31, 2024. The number of employees decreased by 43 or -30.71% compared to the previous year.
Employees
97
Change (1Y)
-43
Growth (1Y)
-30.71%
Revenue / Employee
n/a
Profits / Employee
-$971,732
Market Cap
207.33M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -43 | -30.71% |
| Dec 31, 2023 | 140 | -1 | -0.71% |
| Dec 31, 2022 | 141 | 35 | 33.02% |
| Dec 31, 2021 | 106 | 31 | 41.33% |
| Dec 31, 2020 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Editas Medicine | 246 |
| ProQR Therapeutics | 166 |
| Molecular Partners AG | 153 |
| Heron Therapeutics | 128 |
| Arcturus Therapeutics Holdings | 111 |
| Compugen | 74 |
| Acumen Pharmaceuticals | 61 |
| Elicio Therapeutics | 32 |
TNYA News
- 9 hours ago - Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy - GlobeNewsWire
- 4 days ago - Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga
- 4 days ago - Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - Reuters
- 4 days ago - Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - GlobeNewsWire
- 7 days ago - Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 - GlobeNewsWire
- 2 months ago - Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones - GlobeNewsWire
- 3 months ago - Tenaya Stock Plunges After $60 Million Equity Offering - Benzinga
- 3 months ago - Tenaya Therapeutics Announces Pricing of Public Offering - GlobeNewsWire